What is William Blair’s Estimate for XENE Q1 Earnings?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities researchers at William Blair issued their Q1 2026 EPS estimates for shares of Xenon Pharmaceuticals in a research report issued on Friday, February 28th. William Blair analyst M. Minter expects that the biopharmaceutical company will post earnings of $0.00 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. William Blair also issued estimates for Xenon Pharmaceuticals’ Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.03) EPS and Q4 2026 earnings at ($1.06) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.05.

A number of other equities research analysts have also recently issued reports on XENE. Needham & Company LLC reaffirmed a “buy” rating and issued a $60.00 target price on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 target price on the stock. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Xenon Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $57.38.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $36.02 on Monday. The company’s 50-day moving average price is $39.17 and its two-hundred day moving average price is $40.30. Xenon Pharmaceuticals has a one year low of $33.27 and a one year high of $47.44. The stock has a market capitalization of $2.76 billion, a PE ratio of -12.77 and a beta of 1.26.

Insider Activity

In related news, CEO Ian Mortimer sold 16,315 shares of the business’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $40.50, for a total transaction of $660,757.50. Following the transaction, the chief executive officer now directly owns 31,302 shares in the company, valued at approximately $1,267,731. The trade was a 34.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. Insiders sold 57,492 shares of company stock worth $2,334,969 over the last three months. 5.52% of the stock is currently owned by insiders.

Institutional Trading of Xenon Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC increased its holdings in Xenon Pharmaceuticals by 144.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock worth $100,506,000 after acquiring an additional 1,507,135 shares during the period. JPMorgan Chase & Co. increased its holdings in Xenon Pharmaceuticals by 1,263.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock worth $38,456,000 after acquiring an additional 905,129 shares during the period. FMR LLC increased its holdings in Xenon Pharmaceuticals by 8.8% during the 4th quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company’s stock worth $294,991,000 after acquiring an additional 607,606 shares during the period. Boxer Capital Management LLC bought a new stake in Xenon Pharmaceuticals during the 4th quarter worth approximately $23,520,000. Finally, Stempoint Capital LP bought a new stake in Xenon Pharmaceuticals during the 4th quarter worth approximately $14,733,000. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.